Interim Analysis of the Phase 1 Open-Label Extension Study of Suvodirsen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping


Clinical Trials

Poster Number: 57


Han Phan, Linda Cripe, Michelle Eagle, Francesco Muntoni, MD, Erik Niks, Volker Straub, Laurent Servais, Teresa Gidaro, Odile Boespflug-Tanguy, Nathalie Goemans, MD, PhD, Vasantha Gowda, Giuseppe Vita, MD, Stefano C. Previtali, Stefan Spinty, Craig Campbell, Nicolas Deconinck, Anirban Majumdar, Pallavi Lonkar, Stephen Schmitz, Xiao Hu, Stephen Lake, Kathryn Wagner, MD, Michael Panzara, MD, MPH


1. Rare Disease Research, LLC, Atlanta, GA, USA, 2. Nationwide Children’s Hospital, Columbus, OH, USA, 3. ATOM International, Ltd, Consett, UK, 4. Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, UK, 5. Leiden University Medical Center, Leiden, Netherlands, 6. Newcastle University, Newcastle-upon-Tyne, UK, 7. CHR de la Citadelle, Liège, Belgium, 8. Hôpital Armand-Trousseau, Paris, France, 9. Robert Debré Hospital, Paris, France, 10. Universitair Ziekenhuis Leuven, Leuven, Belgium, 11. Evelina London Children's Hospital, London, UK, 12. University of Messina, Messina, Italy, 13. San Raffaele Scientific Institute (IRCCS), Milan, Italy, 14. Alder Hey Children's Hospital, Liverpool, UK, 15. Western University, London, ON, Canada, 16. UZ Gent and Hôpital Universitaire des Enfants, Université Libre de Bruxelles, Brussels, Belgium, 17. Bristol Children's Hospital, Bristol, UK, 18. Wave Life Sciences Ltd, Cambridge, MA, USA, 19. Wave Life Sciences Ltd, Cambridge, MA, USA, 20. Wave Life Sciences Ltd, Cambridge, MA, USA, 21. Wave Life Sciences Ltd, Cambridge, MA, USA, 22. Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA, 23. Wave Life Sciences Ltd, Cambridge, MA, USA

Background: Suvodirsen is a stereopure antisense oligonucleotide recently under investigation as a therapy for Duchenne muscular dystrophy patients amenable to exon 51 skipping. The Phase 1 open-label extension (OLE) study was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory functional effects of weekly suvodirsen for 96 weeks.
Objectives: To report the analysis of safety, tolerability, and dystrophin levels from baseline to 12 or 22 weeks in the Phase 1 OLE study of suvodirsen.
Approach: The interim analysis was from a global multicenter OLE study of suvodirsen in patients who previously enrolled in a Phase 1 study. A total of 36 patients enrolled in the OLE and received doses of either 3.5 mg/kg or 5 mg/kg. A baseline deltoid muscle biopsy was collected prior to OLE dosing. A second biopsy was collected after 12 or 22 weeks of treatment at 3.5 or 5 mg/kg. A quantitative western blot was used to assess changes in dystrophin amount. Safety assessments included adverse events, physical exams, vital signs, electrocardiogram, and clinical laboratory evaluations.
Results: At data cut-off, follow-up deltoid muscle biopsies were available for 27 of 36 patients. Within the 5 mg/kg arm, 10 patients received follow-up muscle biopsies at 12 weeks and nine patients received follow-up biopsies at 22 weeks. Within the 3.5 mg/kg arm, eight patients received follow-up muscle biopsies at 22 weeks. Muscle biopsies showed no change from baseline in dystrophin expression with either the 3.5 mg/kg or 5 mg/kg suvodirsen doses. No safety concerns or emerging safety signals were observed.
Conclusions: Based on Phase 1 OLE results showing no change from baseline in dystrophin expression, development of suvodirsen has been discontinued. Work is ongoing to fully analyze these results with the intention to share with the DMD community and hopefully advance the development of new DMD treatments.